GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Cyclically Adjusted PB Ratio

NeuBase Therapeutics (NeuBase Therapeutics) Cyclically Adjusted PB Ratio : 0.00 (As of Apr. 27, 2024)


View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-04-27), NeuBase Therapeutics's current share price is $0.4396. NeuBase Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was $209.78. NeuBase Therapeutics's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for NeuBase Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, NeuBase Therapeutics's highest Cyclically Adjusted PB Ratio was 0.01. The lowest was 0.00. And the median was 0.00.

NBSE's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.72
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NeuBase Therapeutics's adjusted book value per share data for the three months ended in Sep. 2023 was $2.450. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $209.78 for the trailing ten years ended in Sep. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


NeuBase Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NeuBase Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Cyclically Adjusted PB Ratio Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.98 0.47 0.61 0.89 0.38

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.02 0.02 0.01 -

Competitive Comparison of NeuBase Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, NeuBase Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuBase Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Cyclically Adjusted PB Ratio falls into.



NeuBase Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NeuBase Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.4396/209.78
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuBase Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, NeuBase Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book=Book Value per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=2.45/129.8595*129.8595
=2.450

Current CPI (Sep. 2023) = 129.8595.

NeuBase Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 86.919 98.326 114.794
201403 61.046 99.695 79.517
201406 463.111 100.560 598.048
201409 423.693 100.428 547.862
201412 357.916 99.070 469.152
201503 642.937 99.621 838.090
201506 601.174 100.684 775.379
201509 560.346 100.392 724.825
201512 502.313 99.792 653.658
201603 451.803 100.470 583.962
201606 368.461 101.688 470.538
201609 311.298 101.861 396.864
201612 287.442 101.863 366.445
201703 207.164 102.862 261.536
201706 199.061 103.349 250.123
201709 162.609 104.136 202.777
201712 139.553 104.011 174.234
201803 125.062 105.290 154.246
201806 121.718 106.317 148.671
201809 -0.297 106.507 -0.362
201812 71.236 105.998 87.272
201903 63.672 107.251 77.094
201906 56.136 108.070 67.455
201909 11.745 108.329 14.079
201912 8.231 108.420 9.859
202003 4.671 108.902 5.570
202006 30.003 108.767 35.821
202009 27.032 109.815 31.966
202012 24.607 109.897 29.077
202103 20.654 111.754 24.000
202106 36.847 114.631 41.742
202109 33.049 115.734 37.083
202112 28.768 117.630 31.759
202203 23.661 121.301 25.330
202206 18.793 125.017 19.521
202209 14.052 125.227 14.572
202212 10.993 125.222 11.400
202303 8.546 127.348 8.715
202306 5.988 128.729 6.041
202309 2.450 129.860 2.450

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeuBase Therapeutics  (NAS:NBSE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NeuBase Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Executives
Symetryx Corp 10 percent owner 2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann officer: COO 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei officer: See Remarks 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall director 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles director 2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast director
Dietrich A Stephan director, 10 percent owner, officer: President and CEO 213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801